Amyris, Inc. (NASDAQ:AMRS) saw a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 2,517,021 shares, a growth of 43.2% from the July 31st total of 1,757,688 shares. Based on an average daily volume of 549,934 shares, the short-interest ratio is currently 4.6 days. Currently, 46.7% of the shares of the stock are short sold.

A hedge fund recently raised its stake in Amyris stock. Carl Domino Inc boosted its stake in Amyris, Inc. (NASDAQ:AMRS) by 37.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 201,925 shares of the biotechnology company’s stock after buying an additional 54,925 shares during the period. Carl Domino Inc owned approximately 0.07% of Amyris worth $107,000 as of its most recent SEC filing. 19.79% of the stock is owned by institutional investors.

Amyris (NASDAQ:AMRS) opened at 2.43 on Thursday. The company’s market cap is $91.38 million. Amyris has a 52-week low of $0.21 and a 52-week high of $18.15. The firm’s 50-day moving average is $3.23 and its 200-day moving average is $5.40.

Amyris (NASDAQ:AMRS) last released its earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by $0.35. The company had revenue of $25.68 million during the quarter, compared to analysts’ expectations of $23.68 million. During the same quarter in the previous year, the business earned ($0.06) EPS. The company’s revenue for the quarter was up 167.5% compared to the same quarter last year. On average, equities research analysts anticipate that Amyris will post ($3.32) EPS for the current year.

Several brokerages recently weighed in on AMRS. Zacks Investment Research upgraded shares of Amyris from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 16th. Cowen and Company set a $4.00 price target on shares of Amyris and gave the stock a “hold” rating in a research report on Thursday, August 17th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Amyris in a research report on Tuesday, May 23rd. Finally, ValuEngine cut shares of Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $25.70.

TRADEMARK VIOLATION WARNING: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.